2023 will be a pivotal year for biosimilar success or failure. Health care expert Fred Goldstein sits down with Stanton Mehr of Biosimilars Review & Report, to discuss what lies in store for biosimilars and AMCP’s biosimilar initiatives this year.
The race, ethnicity, and language Health Equity Action Brief includes an overview of the importance, standards, challenges, and opportunities of these inequities. Additionally, it features examples of how plans are addressing them.
During this sponsored webinar, we will overview Alzheimer's Disease (AD), discuss key considerations during the patient journey, and examine the potential impact of early intervention on the financial burden associated with AD.
February 2023 Legislative & Regulatory Briefing: AMCP CEO Susan Cantrell Reflects on PIE Act Passage; AMCP Joins Health Care Organizations in a Statement on Health Equity; AMCP Responds to Notice of Benefits and Payment Parameters for 2024; AMCP Offers Comments on Essential Health Benefits; AMCP Comments on Proposed Rule to Strengthen the Medicare Advantage and Part D Programs.
Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up! sits down with Jennifer Graff, Senior Director of Professional Affairs at AMCP, to discuss trends to be watching regarding digital therapeutics and managed care pharmacy in 2023.
On Dec. 27, the Centers for Medicare and Medicaid Services (CMS) unveiled a Notice of Proposed Rulemaking (NPRM) on improvements to the Medicare Advantage and prescription drug programs. In a Feb. 13 comment letter, AMCP offers suggestions for strengthening CMS' Medication Therapy Management program, accessible format requirements, and approved formulary, as well as proposals to increase health equity in Medicare Advantage.